11 studies found for:    9058730 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Drug: Decitabine
2 Withdrawn Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na Concentrate
3 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
4 Completed Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Antithymocyte globulin;   Drug: Cyclosporine
5 Unknown  Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies
Condition: Hematological Malignancies
Intervention: Procedure: Intrabone cord blood infusion
6 Terminated SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Beta Erythropoietin
7 Terminated Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
Condition: Myelodysplastic Syndrome
Intervention: Drug: Darbepoetin alfa
8 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
9 Recruiting Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Sirolimus;   Drug: Azacitidine
10 Recruiting Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES
Condition: Myelodysplastic Syndrome
Intervention:
11 Completed Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS
Condition: Myelodysplastic Syndrome
Intervention: Drug: Panhematin

Indicates status has not been verified in more than two years